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We report the 3D structure of human 2 adrenergic receptor (AR)
predicted by using the MembStruk first principles method. To validate
this structure, we use the HierDock first principles method to predict
the ligand-binding sites for epinephrine and norepinephrine and for
eight other ligands, including agonists and antagonists to 2 AR and
ligands not observed to bind to 2 AR. The binding sites agree well
with available mutagenesis data, and the calculated relative binding
energies correlate reasonably with measured binding affinities. In
addition, we find characteristic differences in the predicted binding
sites of known agonists and antagonists that allow us to infer the
likely activity of other ligands. The predicted ligand-binding proper-
ties validate the methods used to predict the 3D structure and
function. This validation is a successful step toward applying these
procedures to predict the 3D structures and function of the other
eight subtypes of ARs, which should enable the development of
subtype-specific antagonists and agonists with reduced side effects.
The adrenergic receptors (ARs) are the class of G protein-coupled receptors (GPCR) responsible for mediating the ef-
fects of the catecholamines epinephrine and norepinephrine. There
are currently nine known human ARs, partitioned into three
subclasses: 1 (three subtypes located in vascular smooth muscle,
the digestive tract, liver, and postsynaptically in the CNS), 2 (three
subtypes located pre- and postsynaptically in the CNS, and in a wide
variety of peripheral sites), and  (three subtypes located
primarily in cardiac, vascular, and adipose tissues, respectively).
The members of this receptor class mediate a wide variety of
physiological responses, including vasodilation and vasoconstric-
tion, heart rate modulation, regulation of lipolysis, and blood
clotting. These diverse and important functions make the adren-
ergic receptors a tempting pharmaceutical target, but attempts to
create effective and specific drugs acting on these receptors have
been slowed down by the lack of a 3D structure for any GPCR other
than the bovine photoreceptor rhodopsin. The focus of this paper
is the 2AR, which is targeted by agonist therapy in the treatment
of asthma. Unfortunately, 2 agonists also exhibit crossreactivity
with the other ARs, causing side effects such as increased heart
rate and blood pressure (1). Three-dimensional models of the ARs
would be extremely useful in the design of subtype-specific
pharmaceutical compounds. In addition, the ARs have been
thoroughly studied experimentally so that there are ample data
for validating the structural predictions, which may in turn
provide improved understanding for the superfamily of GPCRs.
We report here the predicted 3D structure of 2AR, which we
use to predict detailed binding sites of agonists and antagonists
to 2AR. This is an excellent case for validation because there
is a wealth of experimental data on ligand-binding sites and
mutational analysis with which to compare our results (2, 3).
We use the MembStruk computational method to predict the
atomic level tertiary structure of GPCRs using only the primary
sequence, and we use the HierDock method to predict the
binding site and binding energy of ligands binding to the protein
(4, 5). These methods have been validated for bovine rhodopsin
(5, 6) where the predicted binding site is in good agreement with
the experimental results. In addition, recent results for human
D2 dopamine receptor (unpublished data) lead to predicted
binding sites and energies for dopamine and D2 agonists and
antagonists that are in good agreement with experimental data.
Materials and Methods
Structure Prediction of GPCRs: The MembStruk Method. The Memb-
Struk method (version 3.5) for predicting the structure of trans-
membrane proteins consists of the following steps (5, 6). All energy and
force evaluations use the DREIDING force field, CHARMM22
(7) charges for the protein, and QM charges for the ligands.
Transmembrane (TM) prediction (TM2ndS). First, we predict the seven
TM domains by using hydropathicity analysis combined with
information from sequence alignments. The extent of each TM
region is predicted by using sequence alignments of 14 input
sequences having sequence identities ranging from 40% to over
90%. Then, we calculate the average hydrophobicity for every
residue position over all these sequences in the multiple se-
quence alignment while averaging over a window size 12 to 20
residues. The baseline for this profile serves as the threshold
value for determining the TM regions.
Position of maximum hydrophobicity. For each TM region, we identify
lipid-accessible residues from the sequence alignments (less
conserved residues) and from analysis of the hydrophobicity
maxima in the sequence. This position of maximum hydropho-
bicity is used to estimate the relative translational orientation of
the helices. We use the Eisenberg scale for hydrophobicity (8).
Assembly of the helix bundle and optimization of the translational
orientation of the helices. The helical axes are oriented according to
the 7.5-Å electron density map of frog rhodopsin (9). The initial
relative translational orientation of each helix is optimized on
placing into the same fitting plane all of the hydrophobic centers
obtained from step 2.
Optimization of helical bends and kinks. We construct canonical
helices for the predicted TM segments and optimize the struc-
tures of the individual helices using energy minimization fol-
lowed by fast torsional Newton–Euler inverse mass operator
method (NEIMO) dynamics (10, 11) for 500 ps. This procedure
optimizes the bends and kinks in each helix.
Monte Carlo optimization of rotational orientation of the helices. The
initial rotational orientation of each helix (about its axis) is
determined by setting the direction of the net hydrophobic
moment of the middle one-third of each helix (about its hydro-
phobic center). Because molecular dynamics is not likely to
surmount the barriers that might separate one good rotational
state from another, we carry out a systematic search in which
each helix is rotated through a grid of rotational angles, for each
value of which the other six helices are optimized sequentially.
Abbreviations: AR, adrenergic receptor; GPCR, G protein-coupled receptor; TM, transmem-
brane; CRMS, rms deviation in alpha carbon coordinates.
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This sampling allows the system to surmount rotational energy
barriers to sample various possible rotational minima for each
helix. This rotational optimization is carried out for each helix in
turn (over the same grid) until there is no longer a change.
Optimization of the assembled helical bundle with an explicit lipid
environment. The optimized helix bundle is further equilibrated by
immersing the protein into a lipid bilayer and performing rigid
body molecular dynamics (12, 13). The helix bundle surrounded
by a lipid bilayer was optimized by using rigid body dynamics.
Loop building. We construct the full GPCR protein by adding
interhelical loops and disulfide bridges to the helix bundle using
WHATIF (14). In 2AR, the second intracellular loop (60 residues
between TM5 and TM6) was truncated by 23 residues in the middle
of the loop (residues 241–264) because such large loops are quite
flexible, leading to a multiplicity of conformations with similar
energies. Because this deletion is in the middle of a 60-residue loop
region and because this loop is on the intracellular side, these
changes should have little effect on the structure of the TM region.
Currently, we omit modeling the amino and carboxyl terminal regions.
Optimization of the final model. We optimize the final structure by
using conjugate gradient minimization of all atoms in the
structure but with lipid fixed.
Validation: Structure prediction for bovine rhodopsin. The only GPCR
with an experimental 3D crystal structure is bovine rhodopsin
(15, 16), making this the best structure for validating Memb-
Struk. Trabanino et al. (6) showed that the TM regions of the
MembStruk-predicted structure for rhodopsin agree with the
crystal structure, to 2.85 Å CRMS (rms deviation in alpha carbon
coordinates) for all of the main chain atoms. This good agree-
ment with the crystal structure indicates that the MembStruk
procedure predicts the helical regions reasonably well, without
using any knowledge of the crystal structure.
Functional Prediction of GPCRs: The HierDock Protocol. The Hier-
Dock ligand-screening protocol follows a hierarchical strategy
for examining ligand-binding conformations and calculating
their binding energies. The steps are as follows.
Scanning. We carry out a coarse grain docking procedure to
generate a set of conformations for ligand binding in the
receptor. Here, we use DOCK 4.0 (17) to generate and score 1,000
configurations, of which 10% were selected by using a buried
surface area cutoff of 85% and by using energy scoring from
DOCK 4.0, for further analysis.
Ligand relaxation. The 100 best conformations selected for each
ligand from step 1 are subjected to all-atom minimization,
keeping the protein fixed but the ligand movable. The solvation
of each of these 100 minimized structures was calculated by using
the analytical volume generalized born (AVGB) continuum
solvation method (18). The binding energies (BE) were calcu-
lated by using BE  [PE (ligand in solvent)  PE (ligand in
protein)] where PE is the potential energy. Then, the 10 struc-
tures based both on binding energies and buried surface areas
were selected from these 100 structures for the next step.
Complex relaxation. We optimize the structure of the receptor
ligand complex allowing the structure of the protein to accom-
modate the ligand. This relaxation is essential to identify the
optimum conformations for the complex. The all-atom receptor
ligand energy minimization was performed on the 10 structures
from the previous step. Using these optimized structures, we
calculate the binding energy as the difference between the
energy of the ligand in the protein and the energy of the ligand
in water. The energy of the ligand in water is calculated by using
DREIDING force field and the analytical volume generalized
born (AVGB) continuum solvation method (18).
Side-chain optimization. We select, from the 10 structures from the
previous step, the one with the maximum number of hydrogen
bonds between ligand and protein. For this structure, we use the
SCREAM side-chain replacement program to reassign all side-
chain rotamers for the residues within 4 Å in the binding pocket
[SCREAM uses a side-chain rotamer library (1,478 rotamers with
a 1.0-Å resolution) with the all-atom DREIDING energy func-
tion to evaluate the energy for the ligand–protein complex].
Scanning the entire receptor for binding sites. To locate the binding
site, we scan the entire protein for potential binding regions. The
entire molecular surface of the predicted structure of 2AR is
mapped, and spheres representing the empty volume of the recep-
tor are generated by using the Sphgen program in the DOCK 4.0 suite
of programs. The entire set of receptor spheres is divided into six
overlapping regions, and epinephrine is used to scan for a
putative binding site. This first pass is carried out by performing
only the first 2 steps of the HierDock protocol described above.
Determination of binding site and binding energy for all ligands. In the
second pass, we then take a 10  10  10-Å cube surrounding
the putative binding site and perform all of the steps of the
HierDock protocol as described above for all ligands in the study.
Validation for function prediction protocol. The HierDock protocol
has been validated by using it to predict the binding site for
aminoacyl t-RNA synthetases (19, 20) and 37 other co-crystals
of globular proteins (21, 22). We also validated HierDock for
binding of a ligand to a GPCR by docking 11-cis-retinal to bovine
rhodopsin (5, 6). The CRMS between crystal structure and the
docked structure for cis-retinal is 0.6 Å, which is excellent
considering that no information of the binding site was assumed.
We have also used HierDock to predict binding to olfactory
receptors and to other GPCRs (4, 5).
Results
Predicted Structure of Human 2AR. Our predicted 2AR structure
shows the same general topology as bovine rhodopsin. There are
kinks at the conserved prolines of TM2 and TM6 and minor
bends in several other helices. The overall 2AR structure
deviates from rhodopsin by 3.96 Å coordinate rms in the alpha
carbons (CRMS) of the TM region (8.49 Å CRMS over the
entire structure). We suspect that this 3D structure represents
the inactive state of the receptor because it seems to predict
binding of agonist and antagonist equally well.
Predicted Binding Site of Epinephrine in 2AR. From the HierDock
protocol described above, the predicted binding site of epineph-
rine is shown in Fig. 1 where epinephrine is nestled between
TM3, 4, 5, and 6 as shown in the top view (Fig. 1B). This figure
also shows the details of the 5.0-Å binding site of epinephrine,
which suggests that the following residues are critical in binding
the epinephrine.
Asp-113 (TM3). Asp-113 forms a salt bridge with the amine (2.9 Å)
of epinephrine and accepts a hydrogen bond from the alkyl OH
group (3.0 Å). The Asp at this position is conserved across all
biogenic amine receptors (whose endogenous ligands all include
a similar amine), and numerous binding studies have shown that
this residue interacts with the amine in epinephrine (2), validat-
ing our predicted binding site. The second oxygen of the
carboxylate of Asp-113 is 3.8 Å from the amine, making the
interaction with this part of the side chain much weaker.
Ser-203, -204, and -207 (TM5). We find that all three serines form a
hydrogen-bonding network with the two-catechol OH groups of
epinephrine as shown in Fig. 2. The four hydrogen bond dis-
tances are 3.1 Å (Ser-203-meta OH), 2.9 Å (Ser-204-meta OH),
3.0 Å (Ser-203-para OH), and 3.1 Å(Ser-207-para OH). Detailed
mutational studies have shown that Ser-204 interacts specifically
with the meta hydroxyl whereas Ser-207 interacts specifically
with the para hydroxyl (2), validating our predicted binding site.
In addition, a recent study indicates that Ser-203 (previously
thought not to be involved in binding) is quite important to
agonist binding, interacting with the meta OH of epinephrine
(23). Our results indicate that Ser-203 interacts with both the
meta and para OH groups to form the elegant hydrogen-bonding
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network shown in Fig. 2. The Ser-203-meta OH interaction is
conserved across all agonists in our study whereas the Ser-203-
para OH interaction was not, indicating that the meta interaction
is probably functionally important whereas the network includ-
ing the para OH may not be vital to agonist recognition. This
conclusion agrees with mutation data indicating that binding of
phenylephrine (epinephrine without the para OH) is not sub-
stantially affected by mutation of Ser-203 (23).
Asn-293 (TM6). This residue donates a hydrogen bond (3.0 Å) to
the alkyl OH of epinephrine, which is also coupled to Asp-113.
Recently, point mutational studies by Shi et al. (24) showed that
Asn-293 is important for binding, and it has been speculated to
recognize the alkyl OH of epinephrine (24). A detailed picture
of the ionic and hydrogen bond interactions between Asp-113,
Asn-293, and the ligand is shown in Fig. 2B.
Ile-169 (TM4). This residue provides a hydrophobic interaction
with the N-methyl group of epinephrine. It is established exper-
imentally that epinephrine binds more strongly to 2AR than
norepinephrine, and this methyl group is the only difference
between these two ligands. Thus, it is plausible that Ile-169 is
responsible for this selectivity
Val-117 (TM3) and Phe-290 (TM6). These residues provide hydropho-
bic interactions (favorable van der Waals interactions) with the
ring of epinephrine. Phe-290 is in a hydrophobic region that also
includes Phe-289 and Trp-286, collectively termed the WXXFF
motif. This motif is conserved throughout the biogenic amine
receptors (24). In our structure, only Phe-290 seems to be
directly involved in binding the ligand, but the other two residues
may act to position it properly while contributing to the hydro-
phobicity of this region of the binding pocket.
Binding Sites of Other Ligands. Predicted binding sites of all other
ligands in the study are shown in Fig. 7 (which is published as
supporting information on the PNAS web site). The predicted
binding site of each ligand is described below; the structures of
these ligands are shown in Fig. 3.
Norepinephrine (native ligand). The predicted binding site is broadly
similar to that of epinephrine, with two exceptions. Ile-169
interacts with the ring of norepinephrine because there is no
N-methyl group in norepinephrine; this change allows the tail of
norepinephrine to have a slightly different shape than in epi-
nephrine. Additionally, in binding to norepinephrine, Asp-113
interacts only with the amine group (not with the hydroxyl group
in the alkyl chain of norepinephrine), but both oxygens of the
carboxylate of Asp-113 are strongly involved (distances of 2.9 Å
and 3.2 Å). Fig. 4 compares the binding conformations of
epinephrine and norepinephrine, along with the location of
Fig. 1. Five-angstrom predicted binding site of epinephrine in the predicted
structure for 2AR. Complete amino acids are shown in the side view (A) and
top view (B) whereas only side chains are shown in (C). Protein model figures
generated by using PYMOL software (31).
Fig. 2. Important hydrogen bond contacts in the predicted binding site of
epinephrine to human 2AR. (A) The hydrogen-bonded network formed be-
tween both catechol hydroxyl groups with all three highly conserved TM5 serines
(S203, S204, and S207). (B) The hydrogen-bonded network involving the highly
conserved TM3 aspartic acid and N293 with binding to the amine of the ligand.
Fig. 3. Structures of all ligands docked to the 2AR in this study.
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Ser-204. We see that epinephrine has a stronger interaction with
this serine than norepinephrine, but a counterclockwise rotation
of helix 5 by 20° could improve the interaction with both
ligands. It is possible that our predicted structure has small errors
in rotational orientation of the helices, or that this potential for
rotation is indicative of domain-level movements that occur
during activation, as will be discussed below.
Isoproterenol (synthetic agonist). All interactions found in the bind-
ing of epinephrine are also found in the binding site for
isoproterenol. However, isoproterenol has a larger alkyl group
than epinephrine, which interacts with additional residues. Thus,
Trp-109 has a direct hydrophobic interaction with this isopropyl
tail whereas Ile-169 seems to interact more strongly. Addition-
ally, Trp-173 (EC2) seems to close over the top of the binding site
to interact with the isopropyl group of isoproterenol.
Salbutamol (2AR-specific agonist). Salbutamol seems to form inter-
actions similar to those of epinephrine and isoproterenol. How-
ever, there is sufficient space in the binding cavity for the t-butyl
group of salbutamol to fit in the same location as the methyl of
epinephrine, interacting with Ile-169, His-172, and Trp-173. The
bulky hydrophobic tails of these three ligands cause them to bind
in a slightly different conformation than norepinephrine and
dopamine, which may contribute to AR subtype specificities and
differences in affinity between adrenergic and dopamine receptors.
Dopamine (native ligand for dopaminergic receptors; weak agonist for2AR).
The predicted binding site of dopamine seems broadly similar to
that of norepinephrine, with two important exceptions. First, the
catechol OHs of dopamine seem to interact only with Ser-203 and
Ser-207 (Ser-204 is over 4.8 Å away). This result may be due to the
lack of a hydrogen bond with Asn-293, which would otherwise pull
the ligand in the direction of Ser-204. Second, because there is
no alkyl OH, Asn-293 does not interact with this part of the
ligand and instead seems to interact weakly with the amine.
Propranolol (synthetic antagonist). Propranolol binds in the same
pocket as the other ligands, but in a substantially different
conformation. Most notable is that the ligand hydroxyl group
forms a bifurcated hydrogen bond with Ser-203 and Ser-204, but
there is no interaction with Ser-207. In addition, it seems that the
C of Ser-203 is also involved in a hydrophobic interaction with
the backbone and ring system of propranolol. The amine of
propranolol seems to interact with Asp-113 (as do the other
ligands), but here the aromatic ring system of the ligand sits
much closer to TM6. As a result the aromatic ring interacts
strongly with Phe-289, Phe-290, and Ile-294. The isopropyl tail
seems to be in the same conformation as for isoproterenol,
interacting with Trp-109. Ile-169 seems to be involved in a
hydrophobic interaction with the alkyl backbone of the ligand.
Butoxamine (2-selective antagonist). Butoxamine binds in a confor-
mation almost identical to that of propranolol, with an aromatic
system interacting with TM6 and a t-butyl group on the amine
that binds in exactly the same position as the same portion of
salbutamol. Oxygens on butoxamine are involved in hydrogen-
bonding interactions with Ser-203 and Ser-204, but there is no
interaction between butoxamine and Ser-207. Although there is
no interaction with Asn-293 in our initially predicted structure,
we find that a 180° rotation of the asparagine side chain allows
a strong interaction between the asparagine amine and a methyl
ether oxygen of butoxamine. This interaction improves the
binding energy by 2.5 kcalmol. The N-isopropyl group seems
to make the same interactions as the hydrophobic tails of
salbutamol and isoproterenol.
Metoprolol (1-selective antagonist). Metoprolol binds to the 2AR
in a conformation that allows its amine group to interact with
Asp-113, while allowing a pair of oxygens in the ligand to interact
with Ser-203 and Ser-204. A third oxygen in metoprolol interacts
with the amine of Trp-109 whereas hydrophobic portions of the
ligand have strong interactions with Phe-290 and Ile-169. Al-
though metoprolol is marketed as a specific 1AR blocker, its
side effect profile indicates it could have some antagonistic
crossreactivity with 2AR, as will be discussed below.
Xamoterol (1-selective agonist) and Atenolol (1-selective antagonist).
The predicted binding sites are shown in Fig. 7, but our calcu-
lations showed that they do not bind appreciably to 2AR.
Discussion
Difference in Agonist and Antagonist Binding Sites. Of the eight most
strongly bound molecules in our calculations, some are known to
act as agonists whereas others act as antagonists. We find that
the binding sites of the known agonists and antagonists described
above show consistently different patterns in the binding site.
Thus, the agonists epinephrine, norepinephrine, salbutamol, and
isoproterenol all form hydrogen bonds with both Ser-204 and
Ser-207, and the antagonists that bind strongly to the receptor
form hydrogen bonds only with Ser-203 (or Ser-203 and Ser-204
for butoxamine), but never Ser-207. This difference between the
binding of epinephrine and butoxamine is shown in Fig. 5. Both
agonists and antagonists have a strong bond to the Asp-113 of
TM3. Based on these results, we suggest that an agonist must
couple strongly to TM5 with both Ser-204 and Ser-207 while also
bonding to TM3 through Asp-113. On the other hand, the
antagonists need to recognize the same size (to block the
agonist) but lead to a more flexible coupling of TM3 and TM5
so that they do not induce the transition to the activated state.
Fig. 4. Comparison of the predicted binding sites of epinephrine (blue) and
norepinephrine(red)tothe2AR.EpinephrineistiltedtowardS204(makingastrong
contact) whereas norepinephrine is tilted slightly away (making a weak contact). Fig. 5. Critical hydrogen-bonding contacts in the binding of butoxamine (A)
and epinephrine (B) to 2AR. Note that butoxamine does not contact S207 (6
Å away) whereas epinephrine has a strong hydrogen bond (3-Å contact).
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Difference in Agonist-Binding Sites. Among the agonists in this
study, we find two slightly different binding conformations.
Isoproterenol, salbutamol, and epinephrine (the stronger ago-
nists for 2AR) bind in a conformation that allows them to form
a strong hydrogen-bonding network with all three of the con-
served TM5 serines (as shown in Fig. 2). In contrast, the weaker
agonists norepinephrine and dopamine form strong contacts
only with Ser-203 and Ser-207, lying rather far from Ser-204. On
the other hand, for both cases, only a small rotation of TM5
would bring Ser-204 into an excellent hydrophilic interaction
with the ligand, while also improving the hydrogen bond angles
to the other two residues. These results suggest that 2AR
activation may be mediated by a rotation of TM5 to optimize
hydrogen bonding with agonist ligands. A small counterclock-
wise (as viewed from the extracellular side) rotation of TM5
would greatly improve the interactions of norepinephrine and
dopamine with Ser-204 (and also Ser-207 for dopamine). It
would also improve the interaction of salbutamol with Ser-207
and that of isoproterenol with Ser-204. Although the hydrogen-
bonding interactions with epinephrine seem optimal in the
docked conformation, it is so close to Ser-203 that it has a minor
van der Waals clash with the C hydrogens of this side chain; a
slight rotation of TM5 could relieve this clash while also allowing
some improvement in the hydrogen bond angles to Ser-203. The
underlying trend behind these interactions is that all of the
agonists seem to bind with their catechol hydroxyls much closer
to the beta carbon position of Ser-203 than those of Ser-204 or
Ser-207, even in cases (such as epinephrine) where hydrogen
bond distances to Ser-204 and Ser-207 are optimal in these
structures. This conformation is possible because the rotamers of
Ser-204 and Ser-207 are fully extended toward the ligand whereas
that of Ser-203 is more parallel with the ring of the ligand
(perpendicular to the cytoplasmic plane). This feature makes it
possible for interactions with all agonists to be improved by a
rotation of TM5 to improve the hydrogen bonding network that
they form with the serines of TM5. This TM5 rotation will improve
the binding to ligand with little or no motion of the ligand, allowing
the binding interactions with TM3 and TM6 to be preserved
through this rotation (we believe that anchoring interactions with
TM3 and TM6 may be what causes the ligand to fall into a slightly
nonoptimal conformation with respect to its TM5 contacts). Thus,
we postulate that all  adrenergic agonists bind strongly to the
three conserved serines in TM5 and exert activating effects by
inducing a rotation of TM5 that may have broad-reaching effects
elsewhere in the protein. In contrast, antagonists do not form
this network of interactions with the TM5 serines, making them
incapable of inducing the conformational changes leading to
activation.
Recent experimental studies indicate that activation of the
2AR involves a movement of TM6 relative to TM5 and TM3
(25), causing disruption of an ionic lock between the cytoplasmic
ends of TM3 and TM6 (26). Detailed interhelical-linkage studies
on the 2AR have shown that modifications that maintain close
contact between the cytoplasmic ends of TM3 and TM6 com-
pletely block receptor activation (27). These results, combined
with Ghanouni’s f luorescence experiments (25), have led to the
conclusion that, on activation, TM6 either rotates slightly coun-
terclockwise (as viewed from the extracellular region) or tilts its
intracellular end toward TM5. It is possible that a small rotation
of TM5 is the critical step in causing the protein to transition to
the activated state. Clearly, the linkage of TM5 and TM6 by the
IL-3 loop must play some key role in this. A recent study on
bacteriorhodopsin showed that a potential-based change in the
conformation of the IL-3 loop may be directly responsible for an
outward tilting of TM6 occurring at the end of the M segment of
the photocycle (28). Although the function of bacteriorhodopsin is
quite different from that of the 2AR, this experiment illustrates
that manipulating the conformation of IL-3 in a seven-TM protein
can cause a meaningful spatial movement of TM6. A similar
mechanism may be involved in activation of the 2AR (and
potentially other GPCRs as well), with the agonist-induced rotation
of TM5 causing the IL-3 loop to change conformations, and thus
leading to a translation of TM6 and a full transition to the
activated state. More detailed studies will be required to deter-
mine the exact relationship between these activation events.
Binding Energies and Interactions of the Various Ligands. Classification
as agonist or antagonist. The analysis of hydrogen-bonding contacts
described above to classify each binding ligand as either an
agonist or antagonist leads to the classifications shown in Fig. 6.
This criterion correctly classifies all ligands as either agonists or
antagonists. We classify dopamine as a weak agonist because it
makes the appropriate serine contacts, but its contact to S204 is
quite weak, and thus dopamine may not be as effective in
inducing the activating conformational change (described above)
as the other agonists in this study.
Comparison of predicted binding energies and effects with experimental
data. The binding energies for all ligands in this study are shown
in Fig. 6. These results are in qualitative agreement with
experiment. Thus, it is known that isoproterenol exhibits the
Fig. 6. Predicted binding energies and contact distances (hydrogen-bonding and ionic) for the ligands of Fig. 4 to 2AR (all distances are heavy atom–heavy
atom). A more positive energy signifies stronger binding. Based on the TM5 criteria described in the text, ligands were classified as either agonists or antagonists;
their experimentally recognized effects are also indicated. Hydrogen bond lengths and electrostatic interactions between the receptor are also shown for each
of five key residues of the protein; strong interactions (contacts 3.5 Å) are shown in bold. An x indicates no interaction. The hydrogen bond in butoxamine
marked with an asterisk indicates a contact that is made only with the side chain of N293 flipped 180o from the simulated conformation, as described in the text.
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strongest binding affinity among the common agonists to 2AR
and that epinephrine binds more strongly than norepinephrine
(2), all in agreement with our calculations. We also find that
salbutamol (known to be a 2-specific agonist) binds quite
strongly, on par with other strong agonists for this receptor. With
only one exception, the results for the agonists, and their relative
ordering, are perfectly in accord with experimental affinities
(29). Only for dopamine is there a deviation between our results
and the known relative affinities for 2AR. Dopamine is known
to bind less strongly than norepinephrine, but we predict it to
bind more strongly. We do not have an explanation for this result
because we find an almost identical binding mode.
We should emphasize that the binding energies reported here
come from energy minimization, corresponding to the binding
enthalpy at 0 K (except that we do not include zero point energy).
The calculations do include solvation effects (based on the
properties of water at 300 K), but they do not include explicit
entropic terms or the temperature corrections in the enthalpy.
Nevertheless, these results provide valuable information about
the active site, including an interpretation of difference between
agonists or antagonists, and indeed the calculated binding
energies show a very good correlation with experimental disso-
ciation constants, particularly when agonists and antagonists are
analyzed separately. A graph comparing our calculated binding
energies with experimental energies is included in Fig. 8 (which
is published as supporting information on the PNAS web site).
Our results suggest that both propranolol and butoxamine act
as antagonists for this receptor. Butoxamine is known to be a
selective antagonist for 2AR whereas propranolol is an uns-
elective  antagonist. The other three ligands considered here
(metoprolol, atenolol, and xamoterol) were designed to be
specific for 1AR. Of these ligands, we find that only metoprolol
binds appreciably to 2AR, and, because it does not interact with
Ser-207, we expect metoprolol to act as an antagonist. This
finding is consistent with the side effect profile for metoprolol,
which indicates the occurrence of breathing problems consistent
with 2AR antagonism (30).
Full analysis of the subtype selectivity of these compounds
(agonists and antagonists) must await completion of similar studies
for 1AR, but the current results are promising, both because
salbutamol (a strong selective 2 agonist) was found to be strongly
active and because two1-specific compounds were found not to bind.
Conclusion
We find that the predicted 3D structure of the 2AR leads to
predicted binding sites of various ligands that are in excellent
agreement with all available experimental data. The predicted
docking conformations for epinephrine and all other ligands with
well characterized binding sites match very closely to experimental
results. Most notably, all experimentally determined hydrophilic
interactions are predicted successfully in our computational models.
The predicted binding site and energetics of other ligands to
the predicted 2AR structure also lead to good agreement with
experiment. Moreover, this analysis leads to a classification of
ligands as either agonists or antagonists, based on whether or not
they interact with both of the highly conserved TM5 serines of
the receptor: Any ligand that binds but does not contact both
serines will act as an antagonist whereas those ligands binding to
both serines will act as agonists. This correlation allows us to
successfully classify all ligands in the study as agonists or antagonists
(or nonbinding), and it may prove useful in predicting the effects
of novel ligands to 2AR or other GPCRs. We hope that
detailed analyses of the reasons behind this correlation may aid
in finding a detailed description of how receptor activation
occurs, both in the 2AR and in other receptors in this family.
This study of 2AR, and other successful recent studies in
other GPCRs, suggests that these ab initio predictions of the 3D
structure and function may be useful for other GPCRs. We
anticipate that these methods may also be useful for predicting
the function of less well characterized GPCRs, such as lipid and
peptide receptors, and may be useful in quickly assaying poten-
tial crossreactivity effects of new compounds. Carrying out
similar studies for the binding site of each ligand to the other
eight adrenergic receptors should help develop an understanding
of the origins of subtype specificities in the ARs.
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